(Q38810603)

6 September 2017

1 reference

title

Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma (English)

1 reference

6 September 2017

Nan Sethakorn

1

1 reference

PubMed ID

27271022

6 September 2017

Peter H O'Donnell

series ordinal

2

1 reference

PubMed ID

27271022

6 September 2017

language of work or name

1 reference

7 June 2016

1 reference

6 September 2017

1 reference

6 September 2017

118

1 reference

6 September 2017

681-691

1 reference

6 September 2017

5

1 reference

Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations

6 September 2017

1 reference

Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines

21 January 2018

1 reference

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

21 January 2018

1 reference

Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation

21 January 2018

1 reference

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

21 January 2018

1 reference

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

21 January 2018

1 reference

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

21 January 2018

1 reference

Activation of FGF receptors by mutations in the transmembrane domain

21 January 2018

1 reference

The A391E mutation enhances FGFR3 activation in the absence of ligand

21 January 2018

1 reference

FGFR3 unliganded dimer stabilization by the juxtamembrane domain

21 January 2018

1 reference

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

21 January 2018

1 reference

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

21 January 2018

1 reference

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

21 January 2018

1 reference

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

21 January 2018

1 reference

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.

21 January 2018

1 reference

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

21 January 2018

1 reference

Oncogenic FGFR3 gene fusions in bladder cancer

21 January 2018

1 reference

Identification of targetable FGFR gene fusions in diverse cancers.

21 January 2018

1 reference

Transforming fusions of FGFR and TACC genes in human glioblastoma

21 January 2018

1 reference

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism

21 January 2018

1 reference

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.

21 January 2018

1 reference

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

21 January 2018

1 reference

FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population

21 January 2018

1 reference

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations

21 January 2018

1 reference

Genomic Characterization of Upper Tract Urothelial Carcinoma

21 January 2018

1 reference

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

21 January 2018

1 reference

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

21 January 2018

1 reference

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors

21 January 2018

1 reference

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma

21 January 2018

1 reference

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

21 January 2018

1 reference

Toward a molecular pathologic classification of urothelial carcinoma.

21 January 2018

1 reference

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

21 January 2018

1 reference

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

21 January 2018

1 reference

Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy

21 January 2018

1 reference

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

21 January 2018

1 reference

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification

21 January 2018

1 reference

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

21 January 2018

1 reference

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

21 January 2018

1 reference

Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity

21 January 2018

1 reference

Urothelial tumorigenesis: a tale of divergent pathways

21 January 2018

1 reference

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

21 January 2018

1 reference

Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma.

21 January 2018

1 reference

Cancer drug resistance: an evolving paradigm

21 January 2018

1 reference

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma

21 January 2018

1 reference

Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

21 January 2018

1 reference

Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy

21 January 2018

1 reference

A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Tran

21 January 2018

1 reference

Phase II study of everolimus in metastatic urothelial cancer

21 January 2018

1 reference

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

21 January 2018

1 reference

Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine.

21 January 2018

1 reference

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

Paths of FGFR-driven tumorigenesis

21 January 2018

1 reference

Fibroblast growth factor receptor-3 in urothelial tumorigenesis

21 January 2018

1 reference

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJU.13552

1 reference

6 September 2017

1 reference

PubMed ID

27271022